Geneva, Oct. 8 -- International Clinical Trials Registry received information related to the study (ISRCTN11364585) titled 'A clinical trial to assess three self-amplifying ribonucleic acid (saRNA) vaccines against Ebola, Marburg, and Lassa fever viruses' on Sept. 26.
Study Type: Interventional
Study Design:
Interventional randomized controlled trial (Safety)
Primary Sponsor: Imperial College London
Condition:
Healthy volunteers
Infections and Infestations
Intervention:
This is a single-blinded, randomised Phase I trial using the online tool "Sealed Envelope" to generate randomisation lists. Healthy participants aged 18 to 50 years will be enrolled at a single centre and immunised via the intramuscular route at week 0 and week ...